Interested in Alpha Teknova, Inc.? Here are five stocks we like better.
Alpha Teknova reported record Q2 revenue of $12.2 million, up 18% year over year, and raised full-year revenue guidance to $45 million–$47 million from $42 million–$44 million.
The company sees significant growth potential as customers advance from catalog products to custom and GMP offerings: GMP customers spend 44 times more than catalog-only buyers, and Teknova expects its first commercial-therapy customer by the end of 2027.
Teknova expects to become adjusted EBITDA-positive in 2027 at annual revenue of $52 million–$57 million, supported by improving biopharma funding, new commercial investments, AI-enabled product configuration and potential bolt-on acquisitions.
Alpha Teknova (NASDAQ:TKNO) Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.
#teknova #revenue #Growth
Alpha Teknova reported record Q2 revenue of $12.2 million, up 18% year over year, and raised full-year revenue guidance to $45 million–$47 million from $42 million–$44 million.
The company sees significant growth potential as customers advance from catalog products to custom and GMP offerings: GMP customers spend 44 times more than catalog-only buyers, and Teknova expects its first commercial-therapy customer by the end of 2027.
Teknova expects to become adjusted EBITDA-positive in 2027 at annual revenue of $52 million–$57 million, supported by improving biopharma funding, new commercial investments, AI-enabled product configuration and potential bolt-on acquisitions.
Alpha Teknova (NASDAQ:TKNO) Chief Financial Officer Matt Lowell said the provider of laboratory and bioprocessing reagents is seeing renewed growth, reporting record second-quarter revenue and raising its full-year outlook as biopharma funding and life-science end markets improve.
#teknova #revenue #Growth
3 months ago
